Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

865 results

• First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 110NCT00456261
• FISATABIIndependent statistical analysis of Feasibility of Improving Sleep Apnea Treatment Adherence After Brain Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04221009).Phase NAResults postedn = 17NCT04221009
• Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2/3Results postedn = 2NCT01259284
• FLAMEIndependent statistical analysis of the FLAME phase 3 trial of QVA149 versus LABA/ICS in COPD, including exacerbation rates, time-to-event analyses, non-inferiority methodology, safety, and statistical interpretation.Phase 3Results postedn = 3,362NCT01782326
• Fluticasone Nasal Spray Patient Preference Study: Complete Statistical AnalysisIndependent statistical analysis of Fluticasone Nasal Spray Patient Preference Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00398476).Phase 3Results postedn = 127NCT00398476
• FOCUSComplete statistical analysis of the FOCUS randomized phase 3 trial comparing liberal and restrictive blood transfusion strategies in surgical patients with cardiovascular disease, including endpoint definitions, reported odds ratios and risk differences,…Phase 3Results postedn = 2,016NCT00071032
• FREAPIndependent statistical analysis of Effectiveness of Standardized Respiratory Physiotherapy in Primary Care (FREAP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01152762).Phase NAResults postedn = 129NCT01152762
• Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006): Complete Statistical AnalysisIndependent statistical analysis of Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 22NCT04370873
• From Innovation to Solutions: Childhood Influenza Vaccination Planning: Complete Statistical AnalysisIndependent statistical analysis of From Innovation to Solutions: Childhood Influenza Vaccination Planning: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01664793).Phase NAResults postedn = 87,665NCT01664793
• Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 10NCT04294641
• G2YMIIndependent statistical analysis of Getting to Yes, Michigan! (G2YMI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05096260).Phase NAResults postedn = 1,180NCT05096260
• GALATHEAIndependent statistical analysis of the phase 3 GALATHEA trial of benralizumab 30 mg and 100 mg versus placebo in moderate to very severe COPD with exacerbation history, covering negative binomial exacerbation-rate ratios,…Phase 3Results postedn = 1,656NCT02138916
• GammozIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 18NCT02911688
• GARGLESIndependent statistical analysis of Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 20NCT04410159
• Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 313NCT01041781
• Gene Signatures of Influenza Vaccine Responses in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Gene Signatures of Influenza Vaccine Responses in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03603509).Phase 4Results postedn = 241NCT03603509
• GINGERIndependent statistical analysis of Ginger's Therapeutic Potential in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03705832).Phase EARLY_1Results postedn = 54NCT03705832
• GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 132NCT04590547
• GO2 PEEPIndependent statistical analysis of Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 2NCT04331366
• GRABM-LIndependent statistical analysis of GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 16NCT01497665
• GRC00097Independent statistical analysis of Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively: primary endpoint results, effect estimate with…Phase 4Results postedn = 90NCT04109222
• GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.Phase 3Results postedn = 1,156NCT01106014
• GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease: Complete Statistical AnalysisIndependent statistical analysis of GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00950807).Phase 2Results postedn = 176NCT00950807
• HEAL-COVIDIndependent statistical analysis of HEAL-COVID (NCT04801940), a randomized phase 3 trial evaluating apixaban and atorvastatin in patients with Covid19.Phase 3n = 2,631NCT04801940
• Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic: Complete Statistical AnalysisIndependent statistical analysis of Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 6,894NCT04385238
• Herbal Treatment for Perennial Allergic Rhinitis: Complete Statistical AnalysisIndependent statistical analysis of Herbal Treatment for Perennial Allergic Rhinitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00456755).Phase 2Results postedn = 126NCT00456755
• HHHFA in COPD Patients, With Chronic Bronchitis: Complete Statistical AnalysisIndependent statistical analysis of HHHFA in COPD Patients, With Chronic Bronchitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03959982).Phase NAResults postedn = 11NCT03959982
• HIBISCUSIndependent statistical analysis of Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 7NCT04860518
• HITCHIndependent statistical analysis of Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 96NCT04397718
• Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE): Complete Statistical AnalysisIndependent statistical analysis of Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02798471).Phase 3Results postedn = 290NCT02798471
• Home Pulmonary Rehabilitation for COPD: Complete Statistical AnalysisIndependent statistical analysis of Home Pulmonary Rehabilitation for COPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03480386).Phase NAResults postedn = 375NCT03480386
• Homeopathic Cold Medicine for Children: Complete Statistical AnalysisIndependent statistical analysis of Homeopathic Cold Medicine for Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00858494).Phase NAResults postedn = 50NCT00858494
• HORIZON 2Independent statistical analysis of A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 304NCT05007080
• HOT-HMVA statistical analysis of the HOT-HMV phase 4 study, including trial design, endpoint methodology, planned analysis, statistical interpretation, and limitations for COPD exacerbation research.n = 13NCT04272879
• Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules: Complete Statistical AnalysisIndependent statistical analysis of Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 47NCT03502070
• Human Lung Responses to Respiratory Pathogens: Complete Statistical AnalysisIndependent statistical analysis of Human Lung Responses to Respiratory Pathogens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01967628).Phase 1/2Results postedn = 98NCT01967628
• Hydrocortisone for BPD: Complete Statistical AnalysisIndependent statistical analysis of Hydrocortisone for BPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01353313).Phase 3Results postedn = 800NCT01353313
• Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04372017).Phase 3Results postedn = 1NCT04372017
• Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 8NCT00728845
• IASISIndependent statistical analysis of Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 143NCT01969799
• IDEAIndependent statistical analysis of Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04425863).Phase NAResults postedn = 167NCT04425863
• IL-17 Neutrophils in CF Lung Inflammation: Complete Statistical AnalysisIndependent statistical analysis of IL-17 Neutrophils in CF Lung Inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02025829).Phase NAResults postedn = 14NCT02025829
• ILA115938Independent statistical analysis of Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 421NCT01573624
• ILLUMINATEIndependent statistical analysis of the ILLUMINATE phase 3 trial of QVA149 versus fluticasone/salmeterol in patients with chronic obstructive pulmonary disease, including trial design, FEV1 AUC endpoint methodology, safety, and statistical interpretation.Phase 3Results postedn = 523NCT01315249
• Immunization To Prevent Acute COPD Exacerbations: Complete Statistical AnalysisIndependent statistical analysis of Immunization To Prevent Acute COPD Exacerbations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03276754).Phase NAResults postedn = 530NCT03276754
• Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 82NCT00610168
• Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 368NCT05116241
• Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 40NCT01488188
• Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 131NCT01730378
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age: primary endpoint results,…Phase 3Results postedn = 692NCT01767376

← All therapeutic areas